Back to News
Market Impact: 0.3
Teva Pharmaceutical Industries Limited Reports Q3 2026 Financial Results and Raises 2026 Outlook for Key Innovative Brands
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Teva reported Q3 2026 revenue of $4.4 billion, down 2% year over year in both U.S. dollars and local-currency terms. The company attributed the decline primarily to global generics revenue, which fell 16% year over year in local currency.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
TEVA-0.45
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge